Volitionrx Limited Revenue Growth Rates (VNRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Volitionrx Limited  (NYSE: VNRX)
 

VNRX's Revenue Growth by Quarter and Year

Volitionrx Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VNRX/growth
https://api.csimarket.com/api/v1/companies/VNRX/fundamentals
https://api.csimarket.com/api/v1/companies/VNRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
VNRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.61
2nd Quarter June 0.40
1st Quarter March 0.99
FY 3.00

VNRXs Annual Revenue
Volitionrx Limited's Revenue in the fiscal year 2025 $ 1.73 millions
Volitionrx Limited's Revenue in the fiscal year 2024 $ 1.23 millions
Volitionrx Limited's Revenue in the fiscal year 2023 $ 0.78 millions
Volitionrx Limited's Revenue in the fiscal year 2022 $ 0.31 millions
Volitionrx Limited's Revenue in the fiscal year 2021 $ 0.09 millions




VNRX Revenue third quarter 2026 Y/Y Growth Comment
Volitionrx Limited reported Revenue surge of 156.17% year on year in the third quarter 2026, to $ 1.61 millions, this is lower than Volitionrx Limited's recent average Revenue surge of 438.49%.

Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Revenue growth. While Volitionrx Limited' s Revenue doubling of 156.17% ranks overall at the positon no. 2985 in the third quarter 2026.


VNRX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 156.17 %
2nd Quarter June -2.44 %
1st Quarter March 296 %
FY   -

Financial Statements
Volitionrx Limited's third quarter 2026 Revenue $ 1.61 millions VNRX's Income Statement
Volitionrx Limited's third quarter 2025 Revenue $ 0.63 millions Quarterly VNRX's Income Statement


VNRX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 303.47 %
2nd Quarter June -59.6 %
1st Quarter March 120 %
FY (Year on Year)   -


Back to VNRX Growth rate Comparisons >> Back to VNRX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #8
Healthcare Sector #413
Overall #2985

Revenue Y/Y Growth Statistics
High Average Low
4593.01 % 438.49 % -100 %
(Dec 31 2021)   (Sep 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #8
Healthcare Sector #413
Overall #2985
Revenue Y/Y Growth Statistics
High Average Low
4593.01 % 438.49 % -100 %
(Dec 31 2021)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Volitionrx Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1138.26 % 95.37 % -100 %
(Dec 31 2020)  


VNRX's III. Quarter Q/Q Revenue Comment
Volitionrx Limited achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 303.47%, to $ 1.61 millions, from $0.40 millions in the second quarter.
VNRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Volitionrx Limited's Revenue growth quarter on quarter, overall rank is 3703.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #542
Overall #3703
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #542
Overall #3703
Revenue Q/Q Growth Statistics
High Average Low
1138.26 % 95.37 % -100 %
(Dec 31 2020)  


VNRX's III. Quarter Q/Q Revenue Comment
Volitionrx Limited achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 303.47%, to $ 1.61 millions, from $0.40 millions in the second quarter.
VNRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Volitionrx Limited's Revenue growth quarter on quarter, overall rank is 3703.


Volitionrx Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 3.44
Y / Y Revenue Growth (TTM) 134.01 %
Year on Year Revenue Growth Overall Ranking # 471
Seqeuential Revenue Change (TTM) 40.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 2553


Cumulative Revenue growth Comment
Although Volitionrx Limited's Annual Revenue growth year on year were below company's average 152.1% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 134.01% year on year, from 86.32% in Jun 30 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 234 to 471.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 114
Overall # 471

Revenue TTM Y/Y Growth Statistics
High Average Low
570.25 %
 152.1 %
14.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 369
S&P 500 # 2553
Cumulative Revenue growth Comment
Although Volitionrx Limited's Annual Revenue growth year on year were below company's average 152.1% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 134.01% year on year, from 86.32% in Jun 30 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 234 to 471.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 114
Overall # 471

Revenue TTM Y/Y Growth Statistics
High Average Low
570.25 %
152.1 %
14.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 369
S&P 500 # 2553




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VNRX's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Vireo Growth Inc.176.80%$ 176.798 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Hyperion Defi inc 167.90%$ 167.900 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions


About Volitionrx Limited Revenue Growth Rates (VNRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Volitionrx Ltd (CIK 93314).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001477932-26-006881
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Volitionrx Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.